A DNA CONSTRUCT ENCODING THE YAP3 SIGNAL PEPTIDE

Abstract: A DNA construct comprising the following sequence: 5'-P-SP-(LP)n-PS-HP-3' wherein P is a promoter sequence, SP is a DNA sequence encoding the yeast aspartic protease 3 (YAP3) signal peptide, LP is a DNA sequence encoding a leader peptide, n is 0 or 1, PS is a DNA sequence encoding a peptide defining a yeast processing site, and HP is a DNA sequence encoding a polypeptide which is heterologous to a selected host organism. The YAP3 signal peptide provides efficient secretion of heterologous proteins in yeast.

Description: A DNA CONSTRUCT ENCODING THE YAP3 SIGNAL PEPTIDE FIELD OF INVENTION The present invention relates to a DNA construct comprising the YAP3 signal peptide for secretion of a heterologous polypeptide, a yeast cell containing the DNA construct and a method of producing heterologous polypeptides in yeast from the DNA construct. BACKGROUND OF THE INVENTION Yeast organisms produce a number of proteins which are synthesized intracellularly, but which have a function outside the cell. Such extracellular proteins are referred to as secreted proteins. These secreted proteins are expressed initially inside the cell in a precursor or a pre-protein form containing a preseguence ensuring effective direction of the expressed product across the membrane of the endoplasmic reticulu (ER) . The presequence, normally named a signal peptide, is cleaved off from the rest of the protein during translocation. Once entered in the secretory pathway, the protein is transported to the Golgi apparatus. From the Golgi the protein can follow different routes that lead to compartments such as the cell vacuole or the cell membrane, or it can be routed out of the cell to be secreted to the external medium (Pfeffer, S.R. and Rothman, J.E. Ann.Rev.Bioche . 56 (1987), 829-852). Several approaches have been suggested for the expression and secretion in yeast of proteins heterologous to yeast. European published patent application No. 88 632 describes a process by which proteins heterologous to yeast are expressed, processed and secreted by transforming a yeast organism with an expression vehicle harbouring DNA encoding the desired protein and a signal peptide, preparing a culture of the transformed organism, growing the culture and recovering the protein from the culture medium. The signal peptide may be the signal peptide of the desired protein itself, a heterologous signal peptide or a hybrid of native and heterologous signal peptide. A problem encountered with the use of signal peptides hetero- logous to yeast might be that the heterologous signal peptide does not ensure efficient translocation and/or cleavage after the signal peptide. The S^_ cerevisiae MFαl (α-factor) is synthesized as a prepro form of 165 amino acids comprising signal-or prepeptide of 19 amino acids followed by a "leader" or propeptide of 64 amino aicds, encompassing three N-linked glycosylation sites followed by (LysArg(Asp/Glu, Ala) 2 _ 3 α-factor) (Kurjan, J. and Herskowitz, I. Cell 3_0 (1982), 933-943). The signal-leader part of the preproMFαl has been widely employed to obtain synthesis and secretion of heterologous proteins in S^ . cerivisiae. Use of signal/leader peptides homologous to yeast is known from i.a. US patent specification No. 4,546,082, European published patent applications Nos. 116 201, 123 294, 123 544, 163 529, and 123 289 and DK patent application No. 3614/83. In EP 123 289 utilization of the S_ t _ cerevisiae a-factor pre¬ cursor is described whereas WO 84/01153 indicates utilization of the Saccharomyces cerevisiae invertase signal peptide and DK 3614/83 utilization of the Saccharomyces cerevisiae PH05 signal peptide for secretion of foreign proteins. US patent specification No. 4,546,082, EP 16 201, 123 294, 123 544, and 163 529 describe processes by which the α-factor signal-leader from Saccharomyces cerevisiae (MFαl or MFα2) is utilized in the secretion process of expressed heterologous proteins in yeast. By fusing a DNA sequence encoding the S. cerevisiea MFαl signal/leader sequence at the 5' end of the gene for the desired protein secretion and processing of the desired protein was demonstrated. A number of secreted proteins are routed so as to be exposed to a proteolytic processing system which can cleave the peptide bond at the carboxy end of two consecutive basic amino acids. This enzymatic activity is in S_ ^ cerevisiae encoded by the KEX 2 gene (Julius, D.A. et al., Cell 37 (1984b), 1075). Processing of the product by the KEX 2 gene product is needed for the secretion of active S_j_ cerevisiae mating factor α (MFα or α- factor) but is not involved in the secretion of active S. cerevisiae mating factor a. The use of the mouse salivary amylase signal peptide (or a mutant thereof) to provide secretion of heterologous proteins expressed in yeast has been described in WO 89/02463 and WO 90/10075. It is the object of the present invention to provide a more efficient expression and/or secretion in yeast of heterologous proteins. SUMMARY OF THE INVENTION It has surprisingly been found that the signal peptide of the yeast aspartic protease 3 is capable of providing improved secretion of proteins expressed in yeast compared to the mouse salivary amylase signal peptide. Accordingly, the present invention relates to a DNA construct comprising the following sequence 5 ■ -P-SP-(LP) n -PS-HP-3• wherein P is a promoter sequence, SP is a DNA sequence encoding the yeast aspartic protease 3 (YAP3) signal peptide, LP is a DNA sequence encoding a leader peptide, n is 0 or 1, PS is a DNA sequence encoding a peptide defining a yeast processing site, and HP is a DNA sequence encoding a polypeptide which is heterologous to a selected host organism. The term "signal peptide" is understood to mean a presequence which is predominantly hydrophobic in nature and present as an N-terminal sequence of the precursor form of an extracellular protein expressed in yeast. The function of the signal peptide is to allow the heterologous protein to be secreted to enter the endoplasmic reticulum. The signal peptide is cleaved off in the course of this process. The YAP3 signal sequence has been reported previously, fused to its native gene (cf. M. Egel- Mitani et al., Yeast 6 . , 1990, pp. 127-137. A DNA construct wherein the YAP3 signal sequence is fused to a DNA sequence encoding a heterologous polypeptide is believed to be novel. The YAP3 signal peptide has not previously been reported to provide efficient secretion of heterologous polypeptides in yeast. In the present context, the expression "leader peptide" is understood to indicate a peptide whose function is to allow the heterologous polypeptide to be directed from the endoplasmic reticulum to the Golgi apparatus and further to a secretory ve¬ sicle for secretion into the medium, (i.e. export of the expressed polypeptide across the cell wall or at least through the cellular membrane into the periplasmic space of the cell) . The expression "heterologous polypeptide" is intended to indicate a polypeptide which is not produced by the host yeast organism in nature. In another aspect, the present invention relates to a recombinant expression vector comprising the DNA construct of the invention. In a further aspect, the present invention relates to a cell transformed with the recombinant expression vector of the invention. In a still further aspect, the present invention relates to a method of producing a heterologous polypeptide, the method comprising culturing a cell which is capable of expressing a heterologous polypeptide and which is transformed with a DNA construct of the invention in a suitable medium to obtain expression and secretion of the heterologous polypeptide, after which the heterologous polypeptide is recovered from the medium. DETAILED DESCRIPTION OF THE INVENTION In a specific embodiment, the YAP3 signal peptide is encoded by the following DNA sequence ATG AAA CTG AAA ACT GTA AGA TCT GCG GTC CTT TCG TCA CTC TTT GCA TCT CAG GTC CTT GGC (SEQ ID No:l) or a suitable modification thereof encoding a peptide with a high degree of homology (at least 60%, more preferably at least 70%, sequence identity) to the YAP3 signal peptide. Examples of suitable modifications" are nucleotide substitutions which do not give rise to another amino acid sequence of the peptide, but which may correspond to the codon usage of the yeast organism into which the DNA sequence is introduced, or nucleotide substitutions which do give rise to a different amino acid sequence of the peptide (although the amino acid sequence should not modified to the extent that it is no longer able to function as a signal peptide) . Other examples of possible modifications are insertion of three or multiples of three nucleotides at either end of or within the sequence, or deletion of three or multiples of three nucleotides at either end of or within the sequence. In the sequence 5'-P-SP-(LP) n -PS-HP-3 ' , n is preferably 1. In other words, although the YAP3 signal peptide may, in some instances, in itself provide secretion and/or processing of the heterologous polypeptide, a leader or pro-peptide sequence is preferably present. The leader may be a yeast MFαl leader peptide or a synthetic leader peptide, e.g. one of the leader peptides disclosed in WO 89/02463 or WO 92/11378 or a derivative thereof capable of effecting secretion of a heterologous polypeptide in yeast. The term "synthetic" is intended to indicate that the leader peptides in question are not found in nature. Synthetic yeast leader peptides may, for instance be constructed according to the procedures described in WO 89/02463 or WO 92/11378. The yeast processing site encoded by the DNA sequence PS may suitably be any paired combination of Lys and Arg, such as Lys- Arg, Arg-Lys, Lys-Lys or Arg-Arg, which permits processing of the heterologous polypeptide by the KEX2 protease of Saccharomyces cerevisiae or the equivalent protease in other yeast species (D.A. Julius et al., Cell 37. 1984, 1075 ff.). If KEX2 processing is not convenient, e.g. if it would lead to cleavage of the polypeptide product, a processing site for another protease may be selected instead comprising an amino acid combination which is not found in the polypeptide product, e.g. the processing site for FX a , Ile-Glu-Gly-Arg (cf. Sambrook, Fritsch and Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989) . The heterologous protein produced by the method of the inven¬ tion may be any protein which may advantageously be produced in yeast. Examples of such proteins are aprotinin, tissue factor pathway inhibitor or other protease inhibitors, insulin or insulin precursors, human or bovine growth hormone, interleukin, glucagon, tissue plasminogen activator, transforming growth factor α or β , platelet-derived growth factor, enzymes, or a functional analogue thereof. In the present context, the term "functional analogue" is meant to indicate a polypeptide with a similar function as the native protein (this is intended to be understood as relating to the nature rather than the level of biological activity of the native protein) . The polypeptide may be structurally similar to 5 the native protein and may be derived from the native protein by addition of one or more amino acids to either or both the C- and N-terminal end of the native protein, substitution of one or more amino acids at one or a number of different sites in the native amino acid sequence, deletion of one or more amino 10 acids at either or both ends of the native protein or at one or several sites in the amino acid sequence, or insertion of one or more amino acids at one or more sites in the native amino acid sequence. Such modifications are well known for several of the proteins mentioned above. 15 The DNA construct of the invention may be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters 22. 1981, pp. 1859-1869, or the method described by Matthes et al., EMBO Journal 3, 1984, pp. 20801-805. According to the phosphoamidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned into the yeast expression vector. It should be noted that the sequence 5'-P-SP-(LP) n -PS-HP-3' need not be prepared in a single 25 operation, but may be assembled from two or more oligonucleotides prepared synthetically in this fashion. One or more parts of the DNA sequence 5 ! -P-SP-(LP) n -PS-HP-3 • may also be of geno ic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA 30 sequences coding for said parts (typically HP) by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook, Fritsch and Maniatis, Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, New York, 1989) . In this case, a genomic or cDNA sequence encoding 35 a signal peptide may be joined to a genomic or cDNA sequence encoding the heterologous protein, after which the DNA sequence may be modified by the insertion of synthetic oligonucleotides encoding the sequence 5'-P-SP-(LP) n -PS-HP-3 ' in accordance with well-known procedures. Finally, the DNA sequence 5 » -P-SP-(LP) n -PS-HP-3 ' may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by annealing fragments of synthetic, genomic or cDNA origin (as appropriate) , the fragments corresponding to various parts of the entire DNA sequence, in accordance with standard techniques. Thus, it may be envisaged that the DNA sequence encoding the signal peptide or the heterologous polypeptide may be of genomic or cDNA origin, while the sequence 5*-P-SP-(LP) n -PS may be prepared synthetically. The recombinant expression vector carrying the sequence 5'-P- SP-(LP) n -PS-HP-3* may be any vector which is capable of replicating in yeast organisms. In the vector, the promoter sequence (P) may be any DNA sequence which shows transcriptional activity in yeast and may be derived from genes encoding proteins either homologous or heterologous to yeast. The promoter is preferably derived from a gene encoding a protein homologous to yeast. Examples of suitable promoters are the Saccharomyces cerevisiae MFαl, TPI, ADH I, ADH II or PGK promoters, or corresponding promoters from other yeast species, e.g. Schizosaccharomvces pombe. Examples of suitable promoters are described by, for instance, Russell and Hall, J. Biol. Chem. 258. 1983, pp. 143-149; Russell, Nature 301. 1983, pp. 167-169; Ammerer, Meth. Enzy ol. 101. 1983, pp. 192-201; Russell et al. , J. Biol. Chem. 258. 1983, pp. 2674-2682; Hitzeman et al, J. Biol. Chem. 225. 1980, pp. 12073-12080; Kawasaki and Fraenkel, Biochem. Biophys. Res. Com . 108. 1982, and T. Alber and G. Kawasaki, J. Mol. Appl. Genet. 1. 1982, pp. 419-434. The sequences indicated above should also be operably connected to a suitable terminator, e.g. the TPI terminator (cf. T. Alber and G. Kawasaki, J. Mol. Appl. Genet. 1. 1982, pp. 419-434), or the yeast CYC1 terminator. The recombinant expression vector of the invention further comprises a DNA sequence enabling the vector to replicate in yeast. Examples of such sequences are the yeast plasmid 2μ replication genes REP 1-3 and origin of replication. The vector may also comprise a selectable marker, e.g. the Schizo- saccharomyces pombe TPI gene as described by P.R. Russell, Gene 40. 1985, pp. 125-130, or the yeast URA3 gene. The procedures used to insert the sequence 5 l -P-SP-(LP) n -PS-HP- 3 • into a suitable yeast vector containing the information necessary for yeast replication, are well known to persons skilled in the art (cf. , for instance, Sambrook, Fritsch and Maniatis, op.cit.) . It will be understood that the vector may be constructed either by first preparing a DNA construct containing the entire sequence and subsequently inserting this fragment into a suitable expression vector, or by sequentially inserting DNA fragments containing genetic information for the individual elements (such as the promoter sequence, the signal sequence, the leader sequence, or DNA coding for the heterologous polypeptide) followed by ligation. The yeast organism transformed with the vector of the invention may be any suitable yeast organism which, on cultivation, pro¬ duces large amounts of the heterologous polypeptide in question. Examples of suitable yeast organisms may be strains of Saccharomyces. such as Saccharomyces cerevisiae. Sac¬ charomyces kluvveri . or Saccharomyces uvarum, Schizosaccharomyces, such as Schizosaccharomvces pombe. Kluyvero vces. such as Kluyveromyces lactis. Yarrowia. such as Yarrowia lipolytica. or Hansenula, such as Hansenula polv orpha. The transformation of the yeast cells may for instance be effected by protoplast formation followed by transformation in a manner known per se. The medium used to cultivate the cells may be any conventional medium suitable for growing yeast organisms. The secreted heterologous protein, a significant proportion of which will be present in the medium in correctly processed form, may be recovered from the medium by conventional procedures including separating the yeast cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, followed by purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, affinity chromatography, or the like. BRIEF DESCRIPTION OF THE DRAWINGS The invention is further described in the following examples with reference to the appended drawings wherein Fig. 1A and IB schematically show the construction of plasmid pLaC257; Fig. 2 shows the DNA sequence and derived amino acid sequence of the EcoRI-Xbal insert in pLaC257 (SEQ ID No:2); Fig. 3A and 3B schematically show the construction of plasmid pLaC242Apr; Fig. 4 shows the DNA sequence and derived amino acid sequence of the EcoRI-Xbal fragment of pAPRScl, wherein the protein sequence shown in italics is derived from the random expression cloned DNA fragment (SEQ ID No:4) ; Fig. 5 schematically shows the construction of plasmid pLaC263; Fig. 6 shows the DNA sequence and derived amino acid sequence of the EcoRI-Xbal fragment of pLaC263 (SEQ ID No:6); Fig. 7A and 7B show the DNA sequence and derived amino acid sequence of human tissue factor pathway inhibitor (TFPI) including its native signal peptide (SEQ ID No:8) Fig. 8A shows the DNA sequence and derived amino acid sequence of the spx3 signal peptide and 212 leader peptide (shown in WO 89/02463) N-terminally fused to the TFPI sequence in plasmid pYES-212 TFPI161-117Q (SEQ ID No:10); Fig. 8B shows the DNA sequence and derived amino acid sequence of the YAP3 signal peptide and 212 leader peptide N-terminally fused to the TFPI sequence in plasmid pYES-yk TFPI161-117Q (SEQ ID No:12) ; and Fig. 9 shows restriction maps of plasmids pYES21, pP- 212TFPI161-117Q; pYES-212TFPI161-117Q and pYES-ykTFPI161-117Q. The invention is further illustrated in the following examples which are not in any way intended to limit the scope of the invention as claimed. EXAMPLES Plasmids and DNA materials All expression plasmids contain 2μ DNA sequences for replication in yeast and use either the S_-_ cerevisiae URA3 gene or the Schizosaccharomyces pombe triose phosphate isomerase gene (POT) as selectable markers in yeast. POT plasmids are described in EP patent application No. 171 142. A plasmid containing the POT-gene is available from a deposited E. coli strain (ATCC 39685) . The POT plasmids furthermore contain the S_. cerevisiae triose phosphate isomerase promoter and terminator (P τpι and T TPI ) . They are identical to pMT742 (M. Egel- Mitani et al., Gene 73. 1988, pp. 113-120) (see fig. 1) except for the region defined by the Sph-Xbal restriction sites encompassing the P τpι and the coding region for signal/leader/product. The URA3 plasmide use P τpI and the iso-I- cytochrome C terminator (T . ) . The P τpI has been modified with respect to the sequence found in pMT742, only in order to facilitate construction work. An internal SphI restriction site has been eliminated by SphI cleavage, removel of single stranded tails and religation. Furthermore, DNA sequences, upstream to and without any impact on the promoter, have been removed by Bal31 exonuclease treatment followed by addition of an SphI restriction site linker. This promoter construction present on a 373 bp Sphl- EcoRI fragment is designated P τpi(5 and when used in plasmids already described this promoter modification is indicated by the addition of a δ to the plasmid name. Finally a number of synthetic DNA fragments have been employed all of which were synthesized on an automatic DNA synthesizer (Applied Biosystems model 380A) using phosphoramidite chemistry and commercially available reagents (S.L. Beaucage and M.H. Caruthers (1981) Tetrahedron Letters 22 . , 1859-1869) . The oligonucleotides were purified by polyacrylamide gel electrophoresis under denaturing conditions. Prior to annealing complementary pairs of such DNA single strands these were kinased by T4 polynucleotide kinase and ATP. All other methods and materials used are common state of the art knowledge (J. Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press) Cold Spring Harbor, N.Y. 1989). Example 1 The modified mouse salivary amylase signal peptide (MSA3 sp ) (described in WO 89/02463) of the expression cassette of plasmid pLSC6315D3 (described in Example 3 of WO 92/11378) which contains a DNA sequence coding for the insulin precursor MI3 (B(l-29)-Ala-Ala-Lys-A(l-21) ) , was replaced with the YAP3 signal peptide in the following steps: A construct for easy exchange of signal peptides was made. Through site-directed mutagenesis an Asp718 site was introduced just prior to the signal initiation codon in pLaC196<5 (cf. WO 89/02463, fig. 5), by the double primer method applying a mutagenic primer NOR494: 3 '-ATTTGCTGCCATGGTACTTTCAGAAGG (SEQ ID No:14) where bold letters indicate mutations and the underlined sequence indicates the initiation codon. The resulting plasmid was termed pLaC196δ-Asp718 (see Fig. 1) . The nucleotide sequence of the region covering the junction between signal peptide and leader peptide of the expression cassette in pLSC6315D3 was modified, by replacing the Apal- HgiAI restriction fragment with a synthetic DNA stretch, NOR 2521/2522: NOR2521: 5'-CAA CCA ATA GAC ACG CGT AAA GAA GGC CTA CAG CAT GAT TAC GAT ACA GAG ATC TTG GAG (SEQ ID No:15) NOR2522: 5•-C CAA GAT CTC TGT ATC GTA ATC ATG CTG TAG GCC TTC TTT ACG CGT GTC TAT TGG TTG GGC C (SEQ ID No:16) The resulting plasmid was termed pLSC6315D3R (see Fig. 1) . The Sphl-Asp718 fragment of pLaC196<5-Asp718 was ligated with Sphl-Mlul cut pLSC6315D3R plasmid and a synthetic stretch of DNA encoding the YAP3 signal peptide: YAP-spl: 5'-GT ACC AAA ATA ATG AAA CTG AAA ACT GTA AGA TCT GCG GTC CTT TCG TCA CTC TTT GCA TCT CAG GTC CTT GGC CAA CCA ATA GAC A (SEQ ID No:17) YAP-sp2: 5'-CG CGT GTC TAT TGG TTG GCC AAG GAC CTG AGA TGC AAA GAG TGA CGA AAG GAC CGC AGA TCT TAC AGT TTT CAG TTT CTA TAT TTT G (SEQ ID No:18) The resulting plasmid pLaC257 essentially consists of pLSC6315D3, in which the MSA3 signal peptide has been replaced by the YAP3 signal peptide (see Fig. 2) . Yeast transformation: S. cerevisiae strain MT663 (E2-7B XE11-36 a/α, Δtpi/Δtpi, pep 4-3/pep 4-3) (the yeast strain MT663 was deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen in connection with filing WO 92/11378 and was given the deposit number DSM 6278) was grown on YPGaL (1% Bacto yeast extract, 2% Bacto peptone, 2% galactose, 1% lactate) to an O.D. at 600 n of 0.6. 100 ml of culture was harvested by centrifugation, washed with 10 ml of water, recentrifugated and resuspended in 10 ml of a solution containing 1.2 M sorbitol, 25 mM Na 2 EDTA pH = 8.0 and 6.7 mg/ml dithiotreitol. The suspension was incubated at 30°C for 15 minutes, centrifuged and the cells resuspended in 10 ml of a solution containing 1.2 M sorbitol, 10 mM Na 2 EDTA, 0.1 M sodium citrate, pH 0 5.8, and 2 mg Novozym ® 234. The suspension was incubated at 30°C for 30 minutes, the cells collected by centrifugation, washed in 10 ml of 1.2 M sorbitol and 10 ml of CAS (1.2 M sorbitol, 10 mM CaCl 2 , 10 mM Tris HCl (Tris = Tris(hydroxymethyl)aminomethane) pH = 7.5) and resuspended in 2 ml of CAS. For transformation, 1 ml of CAS-suspended cells was mixed with approx. 0.1 μg of plasmid pLaC257 and left at room temperature for 15 minutes. 1 ml of (20% polyethylene glycol 4000, 20 mM CaCl 2 , 10 mM CaCl 2 , 10 mM Tris HCl, pH = 7.5) was added and the mixture left for a further 30 minutes at room temperature. The mixture was centrifuged and the pellet resuspended in 0.1 ml of SOS (1.2 M sorbitol, 33% v/v YPD, 6.7 mM CaCl 2 , 14 μg/ml leucine) and incubated at 30°C for 2 hours. The suspension was then centrifuged and the pellet resuspended in 0.5 ml of 1.2 M sorbitol. Then, 6 ml of top agar (the SC medium of Sherman et al., Methods in Yeast Genetics. Cold Spring Harbor Laboratory (1982)) containing 1.2 M sorbitol plus 2.5%agar) at 52°C was added and the suspension poured on top of plates containing the same agar-solidified, sorbitol containing medium. Transformant colonies were picked after 3 days at 30°C, reisolated and used to start liquid cultures. One transformant was selected for further characterization. Fermentation: Yeast strain MT663 transformed with plasmid pLaC257 was grown on YPD medium (1% yeast extract, 2% peptone (from Difco Laboratories) , and 3% glucose) . A 1 liter culture of the strain was shaken at 30°C to an optical density at 650 n of 24. After centrifugation the supernatant was isolated. MT663 cells transformed with plasmid pLSC6315D3 and cultured as described above were used for a comparison of yields of MI3 insulin precursor. Yields of MI3 were determined directly on culture supernatants by the method of Snel, Damgaard and Mollerup, Chromatographia 24. 1987, pp. 329-332. The results are shown below. Example 2 Plasmid pLSC6315D3 was modified in two steps. First, the MSA3 signal peptide was replaced by the spx3 signal peptide by exchanging the Sphl-Apal fragment with the analogous fragment from pLaC212spx3 (cf. WO 89/02463) . From the resulting plasmid pSLC63.15spx3, a 302bp EcoRl-Ddel fragment was isolated and fused to the 204 bp Ncol-Xbal fragment of pKFN1003 (WO 90/10075) containing the DNA sequence encoding aprotinin via a synthetic linker DNA, NOR2101/2100 (see Fig. 3) NOR2101: 5'-T AAC GTC GC (SEQ ID No:19) NOR2100: 5'-CAT GGC GAC G (SEQ ID No:20) The resulting plasmid, pLaC242-Apr (see Fig. 3) , was cleaved with Clal, dephosphorylated and applied in cloning of random 5'-CG-overhang fragments of DNA isolated from S. cerevisiae strain MT663, according to the description in WO 92/11378. Transformation and fermentation of yeast strain MT663 was carried out as described in Example 1. From the resulting library yeast transformants harbouring the plasmid pAPR-Scl (prepared by the method described in WO 92/11378) containing a leader the sequence of which is given in Fig. 4, was selected by screening. The spx3 signal peptide of pAPR-Scl was replaced by the YAP3 signal peptide by fusing the Sphl-Styl fragment from pLaC257 with the 300 bp Nhel-Xbal fragment of pAPR-Scl via the synthetic linker DNA MH1338/1339 (see Fig. 5) : MH 1338: 5'-CTT GGC CAA CCA TCG AAA TTG AAA CCA G (SEQ ID No:21) MH 1339: 5'-CT AGC TGG TTT CAA TTT CGA TGG TTG GC (SEQ ID No:22) The resulting plasmid was termed pLaC263 (see Fig. 5) . The DNA sequence and derived amino acid sequence of the EcoRI-Xbal fragment of pLaC263 appears from Fig. 6. plasmid aprotinin yield pAPR-Scl (Spx3 sp ) 100% pLaC263 136% Example 3 A synthetic gene coding for human TFPI, the DNA sequence of which was derived from the published sequence of a cDNA coding for human tissue factor pathway inhibitor (TFPI) (Wun et al., J. Biol. Chem. 263 (1988) 6001-6004), was prepared by step-wise cloning of synthetic restriction fragments into plasmid pBS(+) . The resulting gene was contained on a 928 base pair (bp) Sail restriction fragment. The gene had 26 silent nucleotide substitutions in degenerate codons as compared to the cDNA resulting in fourteen unique restriction endonuclease sites. The DNA sequence of the 928 bp Sail fragment and the corresponding amino acid sequence of human TFPI (pre-form) is shown in Fig. 7 (SEQ ID No:8). This DNA sequence was subsequently truncated to code for a TFPI variant composed of the first 161 amino acids. A non- glycosylated variant, TFPI 1 . 161 -ll7Gln in which the AAT-codon for Asnll7 was replaced by CAA coding for Gin was constructed by site-directed mutagenesis in a manner known per se using synthetic oligonucleotides. The DNA sequence encoding TFPI.,_ 161 - 117Gln was preceded by the synthetic signal-leader sequence 212spx3 (cf. WO 89/02463) , see Fig. 8A. This construction was inserted into the plasmid pP-212TFPI161-117Q (based on a vector of the POT-type (G. Kawasaki and L. Bell, US patent 4,931,373), cf. Fig. 8) . A 1.1 kb Sphl-Xbal fragment containing the coding region for 2l2spx3-TFPI 1.161 -ll7Gln was isolated and cloned into the plasmid pYES21 derived from the commercially available (Stratagene) vector pYES2.0 (cf. Fig. 8). This plasmid contains 2μ sequence for replication in yeast, the yeast URA3 gene for plasmid selection in ura3 strains, the 3-lactamase gene for selection in E. coli. the ColEl origin of replication for replication in E. coli. the fl origin for recovery of single-stranded DNA 5 plasmid from superinfected E. coli strains, and the yeast CYCl transcriptional terminator. The Sphl-Xbal fragment was cloned into pYES 2.0 in front of the CYCl terminator.The resulting plasmid pYES-212TFPI161-117Q (cf. Fig. 9) was cleaved with PflMI and EcoRI to remove the coding region for the mouse 10 salivary amylase signal peptide which was replaced by a double- stranded synthetic oligonucleotide sequence coding for the YAP3 signal peptide: MHJ 1131 5 » AAT TCA AAC TAA AAA ATG AAG CTT AAA ACT GTA AGA TCT GCG GTC CTT TCG TCA CTC TTT GCA TCG CAG GTC CTA GGT CAA CCA 15 GTC A (SEQ ID No:23) MHJ 1132 5'CTG GTT GAC CTA GGA CCT GCG ATG CAA AGA GTG ACG AAA GGA CCG CAG ATC TTA CAG TTT TAA GCT TCA TTT TTT AGT TTG (SEQ ID No:24) resulting in plasmid pYES-ykTFPI161-117Q (cf. Fig. 8B and Fig. 209) . Plasmids pYES-212TFPI161-117Q and pYES-ykTFPI161-117Q were transformed into the haploid yeast strain YNG318 (MATα ura3-52 leu2-42 pep4-,4l his4-539 fcir+1. Plasmid selection was for Ura+ cells. Reisolated transformants were grown in 50 ml of 25 synthetic complete medium lacking uracil (SC-ura) for 3 days at 30°C. After measuring cell density (OD 600 ) , the cultures were centrifuged and the resulting supernatants were analysed for the level of secreted FXa/TF/FVIIa-dependent chromogenic TFPI- activity (P.M. Sandset et al., Thromb.Res. 47. 1987, pp. 389- 30400) . The mean activity measured for supernatants from strains containing plasmid pYES-212TFPI161-117Q (i.e. the plasmid containing the mouse salivary amylase signal sequence) was 0.65 U/ml»OD. The mean activity measured for supernatants from strains containing plasmid pYES-ykTFPI161-H7Q was 1.00 U/ml»OD. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPHECANT: (A) NAME: Novo Nordisk A S (B) STREET: Novo Alle (C) CITY: Bagsvaerd (E) COUNTRY: Denmark (F) POSTAL CODE (ZIP) : 2880 (G) TELEPHONE: +45 4444 8888 (H) TELEFAX: +45 4449 3256 (ii) TITLE OF INVENTION: A DNA Construct Encoding the YAP3 Signal Peptide (iii) NUMBER OF SEQUENCES: 24 (iv) CCMHJIER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMEUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFIWARE: Patentin Release #1.0, Version #1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 63 base pairs (B) TYPE: nucleic acid (C) STRANDEENESS: single (D) TOPOIDGY: linear (ii) MD ECULE TYPE: cENA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Sacchartaπyces cerevisiae (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: ATGAAACTGA AAACIGTAAG ATCIGOGGTC CΠTCGTCAC TCTTTGCATC TCAGGTCCTT 60 GGC 63 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 476 base pairs (B) TYPE: nucleic acid (C) STRANDEENESS: single (D) TOPOI GY: linear (ii) M3LECULE TYPE: DNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (ix) FEATURE: (A) NAME/KEY: CDS (B) IDCAΠON: 81. .452 (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION: 81. .293 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) IDCAπON: 294. .452 (XI) SEQUENCE DESCRIPTION: SEQ ID NO: 2: GAATΓCATΓC AAGAATACTT CAAACAAGAA GAΠACAAAC TATCAA ΓΓC ATACACAATA 60 TAAACGACGG TACCAAAATA ATG AAA CTG AAA ACT GTA AGA TCT GCG GTC 110 Met Lys Leu Lys Thr Val Arg Ser Ala Val -71 -70 -65 CTT TCG TCA CTC TTT GCA TCT CAG GTC CTT GGC CAA CCA ATA GAC ACG 158 Leu Ser Ser Leu Fhe Ala Ser Gin Val Leu Gly Gin Pro lie Asp Thr -60 -55 -50 CGT AAA GAA GGC CTA CAG CAT GAT TAC GAT ACA GAG ATC TTG GAG CAC 206 Arg Lys Glu Gly Leu Gin His Asp Tyr Asp Thr Glu lie Leu Glu His -45 -40 -35 -30 AIT GGA AGC GAT GAG TTA ATT TTG AAT GAA GAG TAT GIT ATT GAA AGA 254 lie Gly Ser Asp Glu leu lie Leu Asn Glu Glu Tyr Val lie Glu Arg -25 -20 -15 ACT TTG CAA GCC ATC GAT AAC ACC ACT TTG GCT AAG AGA TTC CTT AAC 302 Thr Leu Gin Ala lie Asp Asn Thr Thr Leu Ala Lys Arg Phe Val Asn -10 -5 1 CAA CAC TTG TGC GGT TCC CAC TTG GIT GAA GCT TTG TAC TTG GTT TGC 350 Gin His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys 5 10 15 GGT GAA AGA GGT TTC TTC TAC ACT CCT AAG GCT GCT AAG GGT ATT GTC 398 Gly Glu Arg Gly Phe Rie Tyr Thr Pro Lys Ala Ala Lys Gly lie Val 20 25 30 35 GAA CAA TGC TGT ACC TCC ATC TGC TCC TTG TAC CAA TTG GAA AAC TAC 446 Glu Gin Cys Cys Thr Ser He Cys Ser Leu Tyr Gin Leu Glu Asn Tyr 40 45 50 TGC AAC TAGACGCAGC CCGCAGGCTC TAGA 476 Cys Asn (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 124 amino acids (B) TYPE: amino acid (D) TOPOIOGY: linear (ii) MDLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Met Lys Leu Lys Thr Val Arg Ser Ala Val Leu Ser Ser Leu Phe Ala -71 -70 -65 -60 Ser Gin Val Leu Gly Gin Pro He Asp Thr Arg Lys Glu Gly Leu Gin -55 -50 -45 -40 His Asp Tyr Asp Thr Glu He Leu Glu His He Gly Ser Asp Glu Leu -35 -30 -25 He Lsu Asn Glu Glu Tyr Val He Glu Arg Thr Leu Gin Ala He Asp -20 -15 -10 Asn Thr Thr Lsu Ala Lys Arg Phe Val Asn Gin His Lsu Cys Gly Ser -5 1 5 His Lsu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe 10 15 20 25 Tyr Thr Pro Lys Ala Ala Lys Gly He Val Glu Gin Cys Cys Thr Ser 30 35 40 He Cys Ser Leu Tyr Gin Lsu Glu Asn Tyr Cys Asn 45 50 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 450 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: DNA (iii) HYPOTHETICAL: NO (iii) ANTT-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (ix) FEATURE: (A) NAME/KEY: CDS (B) DCAΠON: 76..441 (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) IOCAπON: 76..267 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 268..441 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: GAATTCATTC AAGAATAGTT CAAACAAGAA GATTACAAAC TATCAATTTC ATACACAATA 60 TAAAOGAITA AAAGA ATG AAG GCT GTT TTC TTG GTT TTG TCC TTG ATC GGA 111 Met Lys Ala Val Phe Leu Val Leu Ser Leu He Gly -64 -60 -55 TTC TGC TGG GCC CAA CCA TCG AAA TTG AAA CCA GCT AGC GAT ATA CAA 159 Hie Cys Trp Ala Gin Pro Ser Lys Leu Lys Pro Ala Ser Asp He Gin -50 -45 -40 AIT CTT TAC GAC CAT GCT GIG AGG GAG TTC GGG GAA AAC TAT GTT CAA 207 He Leu Tyr Asp His Gly Val Arg Glu Fhe Gly Glu Asn Tyr Val Gin -35 -30 -25 GAG TTG ATC GAT AAC ACC ACT TTG GCT AAC GTC GCC ATG GCT GAG AGA 255 Glu Leu He Asp Asn Thr Thr Leu Ala Asn Val Ala Met Ala Glu Arg -20 -15 -10 -5 TTG GAG AAG AGA AGG CCT GAT TTC TGT TTG GAA CCT CCA TAC ACT GGT 303 leu Glu Lys Arg Arg Pro Asp Fhe Cys Leu Glu Pro Pro Tyr Thr Gly 1 5 10 CCA TGT AAA GCT AGA ATC ATC AGA TAC TTC TAC AAC GCC AAG GCT GGT 351 Pro Cys Lys Ala Arg He He Arg Tyr Phe Tyr Asn Ala Lys Ala Gly 15 20 25 TTG TGT CAA ACT TTC GTT TAC GCT GGC TGC AGA GCT AAG AGA AAC AAC 399 Leu Cys Gin Thr Phe Val Tyr Gly Gly Cys Arg Ala Lys Arg Asn Asn 30 35 40 TTC AAG TCT GCT GAA GAC TGC ATG AGA ACT TGT GGT GGT GCC 441 Fhe Lys Ser Ala Glu Asp Cys Met Arg Thr Cys Gly Gly Ala 45 50 55 TAATCTAGA 450 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTTCS: (A) LENGTH: 122 amino acids (B) TYPE: amino acid (D) TOPOIOGY: linear (ii) MDLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: Met Lys Ala Val Fhe Lsu Val Leu Ser Lsu He Gly Fhe Cys Trp Ala -64 -60 -55 -50 Gin Pro Ser Lys Lsu Lys Pro Ala Ser Asp He Gin He Leu Tyr Asp -45 -40 -35 His Gly Val Arg Glu Phe Gly Glu Asn Tyr Val Gin Glu Leu He Asp -30 -25 -20 Asn Thr Thr Lsu Ala Asn Val Ala Met Ala Glu Arg Leu Glu Lys Arg -15 -10 -5 Arg Pro Asp Fhe Cys Leu Glu Pro Pro Tyr Thr Gly Pro Cys Lys Ala 1 5 10 15 Arg He He Arg Tyr Fhe Tyr Asn Ala Lys Ala Gly Leu Cys Gin Thr 20 25 30 Fhe Val Tyr Gly Gly Cys Arg Ala Lys Arg Asn Asn Fhe Lys Ser Ala 35 40 45 Glu Asp Cys Met Arg Thr Cys Gly Gly Ala 50 55 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 470 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: DNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (ix) FEATURE: (A) NAME/KEY: CDS (B) IOCATTON: 81..461 (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION: 81..287 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 288..461 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: GAATTCATΓC AAGAAIAGTT CAAACAAGAA GAITACAAAC TATCAATTTC ATACACAATA 60 TAAACGACGG TACCAAAATA ATG AAA CTG AAA ACT GTA AGA TCT GCG GTC 110 Met Lys Lsu Lys Thr Val Arg Ser Ala Val -69 -65 -60 CTT TCG TCA CTC TTT GCA TCT CAG GTC CTT GGC CAA CCA TCG AAA TTG 158 Leu Ser Ser Leu Phe Ala Ser Gin Val Lsu Gly Gin Pro Ser Lys Leu -55 -50 -45 AAA CCA GCT AGC GAT ATA CAA ATT CTT TAC GAC CAT GGT GIG AGG GAG 206 Lys Pro Ala Ser Asp He Gin He Lsu Tyr Asp His Gly Val Arg Glu -40 -35 -30 TTC GGG GAA AAC TAT GTT CAA GAG TTG ATC GAT AAC ACC ACT TTG GCT 254 Phe Gly Glu Asn Tyr Val Gin Glu Leu He Asp Asn Thr Thr Leu Ala -25 -20 -15 AAC CTC GCC ATG GCT GAG AGA TTG GAG AAG AGA AGG CCT GAT TTC TGT 302 Asn Val Ala Met Ala Glu Arg Leu Glu Lys Arg Arg Pro Asp Fhe Cys -10 -5 1 5 TTG GAA CCT CCA TAC ACT GGT CCA TGT AAA GCT AGA ATC ATC AGA TAC 350 Leu Glu Pro Pro Tyr Thr Gly Pro Cys Lys Ala Arg He He Arg Tyr 10 15 20 TTC TAC AAC GCC AAG GCT GGT TTG TGT CAA ACT TTC GTT TAC GGT GGC 398 Fhe Tyr Asn Ala Lys Ala Gly Leu Cys Gin Thr Fhe Val Tyr Gly Gly 25 30 35 TGC AGA GCT AAG AGA AAC AAC TTC AAG TCT GCT GAA GAC TGC ATG AGA 446 Cys Arg Ala Lys Arg Asn Asn Fhe Lys Ser Ala Glu Asp Cys Met Arg 40 45 50 ACT TGT GGT GGT GCC TAATCTAGA 470 Thr Cys Gly Gly Ala 55 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 127 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: Met Lys Leu Lys Thr Val Arg Ser Ala Val Leu Ser Ser Leu Ehe Ala -69 -65 -60 -55 Ser Gin Val Leu Gly Gin Pro Ser Lys Leu Lys Pro Ala Ser Asp He -50 -45 -40 Gin He Lsu Tyr Asp His Gly Val Arg Glu Ehe Gly Glu Asn Tyr Val -35 -30 -25 Gin Glu Leu He Asp Asn Thr Thr Leu Ala Asn Val Ala Met Ala Glu -20 -15 -10 Arg Leu Glu Lys Arg Arg Pro Asp Fhe Cys Leu Glu Pro Pro Tyr Thr -5 1 5 10 Gly Pro Cys Lys Ala Arg He He Arg Tyr Phe Tyr Asn Ala Lys Ala 15 20 25 Gly Lsu Cys Gin Thr Ehe Val Tyr Gly Gly Cys Arg Ala Lys Arg Asn 30 35 40 Asn Ehe Lys Ser Ala Glu Asp Cys Met Arg Thr Cys Gly Gly Ala 45 50 55 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTTCS: (A) LENGTH: 928 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: CENA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 8..919 (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION: 8. .91 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 92. .919 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: GTCGACC ATG ATT TAC ACA ATG AAG AAA GTA CAT GCA CTT TGG GCT AGC 49 Met He Tyr Thr Met Lys Lys Val His Ala Leu Trp Ala Ser -28 -25 -20 -15 GTA TGC CTG CTG CTT AAT CTT GCC CCT GCC CCT CTT AAT GCT GAT TCT 97 Val Cys Lsu Leu Leu Asn Leu Ala Pro Ala Pro Leu Asn Ala Asp Ser -10 -5 1 GAG GAA GAT GAA GAA CAC ACA ATT ATC ACA GAT ACG GAG CTC CCA CCA 145 Glu Glu Asp Glu Glu His Thr He He Thr Asp Thr Glu Leu Pro Pro 5 10 15 CTG AAA CTT ATG CAT TCA TTT TGT GCA TTC AAG GCG GAT GAT GGG GCC 193 Leu Lys Lsu Met His Ser Fhe Cys Ala Fhe Lys Ala Asp Asp Gly Pro 20 25 30 TGT AAA GCA ATC ATG AAA AGA TTT TTC TTC AAT ATT TTC ACT CGA CAG 241 Cys Lys Ala He Met Lys Arg Fhe Phe Phe Asn He Fhe Thr Arg Gin 35 40 45 50 TGC GAA GAA TTT ATA TAT GGG GGA TGT GAA GGA AAT CAG AAT CGA TTT 289 Cys Glu Glu Fhe He Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Ehe 55 60 65 GAA ACT CTG GAA GAG TGC AAA AAA ATG TGT ACA AGA GAT AAT GCA AAC 337 Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp Asn Ala Asn 70 75 80 AGG ATT ATA AAG ACA ACA CTG CAG CAA GAA AAG CCA GAT TTC TGC TTT 385 Arg He He Lys Thr Thr Leu Gin Gin Glu Lys Pro Asp Phe Cys Phe 85 90 95 TTG GAA GAG GAT CCT GGA ATA TGT CGA GGT TAT AIT ACC AGG TAT TTT 433 Leu Glu Glu Asp Pro Gly He Cys Arg Gly Tyr He Thr Arg Tyr Phe 100 105 110 TAT AAC AAT CAG ACA AAA CAG TGT GAA AGG TTC AAG TAT GGT GGA TGC 481 Tyr Asn Asn Gin Thr Lys Gin Cys Glu Arg Fhe Lys Tyr Gly Gly Cys 115 120 125 130 CTG GGC AAT ATG AAC AAT TTT GAG ACA CTC GAG GAA TGC AAG AAC ATT 529 Leu Gly Asn Met Asn Asn Ehe Glu Thr Lsu Glu Glu Cys Lys Asn He 135 140 145 TGT GAA GAT GGT CCG AAT GGT TTC CAG GTG GAT AAT TAT GCT ACC CAG 577 Cys Glu Asp Gly Pro Asn Gly Fhe Gin Val Asp Asn Tyr Gly Thr Gin 150 155 160 CTC AAT GCT GTT AAC AAC TCC CTG ACT CCG CAA TCA ACC AAG GTT CCC 625 Leu Asn Ala Val Asn Asn Ser Leu Thr I>ro Gin Ser Thr Lys Val Pro 165 170 175 AGC CTT TTT GAA TTC CAC GGT CCC TCA TGG TGT CTC ACT CCA GCA GAT 673 Ser Leu Fhe Glu Ehe His Gly Pro Ser Trp Cys Lsu Thr Fto Ala Asp 180 185 190 AGA GGA TTG TGT CCT GCC AAT GAG AAC AGA TTC TAC TAC AAT TCA GTC 721 Arg Gly Leu Cys Arg Ala Asn Glu Asn Arg Ehe Tyr Tyr Asn Ser Val 195 200 205 210 ATT GGG AAA TGC CGC CCA TTT AAG TAC TCC GGA TCT GGG GGA AAT GAA 769 He Gly Lys Cys Arg Pro Fhe Lys Tyr Ser Gly Cys Gly Gly Asn Glu 215 220 225 AAC AAT TTT ACT ACT AAA CAA GAA TCT CTG AGG GCA TGC AAA AAA GCT 817 Asn Asn Phe Thr Ser Lys Gin Glu Cys Lsu Arg Ala Cys Lys Lys Gly 230 235 240 TTC ATC CAA AGA ATA TCA AAA GGA GGC CTA ATT AAA ACC AAA AGA AAA 865 Fhe He Gin Arg He Ser Lys Gly Gly Leu He Lys Thr Lys Arg Lys 245 250 255 AGA AAG AAG CAG AGA GTG AAA ATA GCA TAT GAA GAA ATT TTT GTT AAA 913 Arg Lys Lys Gin Arg Val Lys He Ala Tyr Glu Glu He Fhe Val Lys 260 265 270 AAT ATG TGACTCGAC 928 Asn Met 275 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 304 amino acids (B) TYPE: amino acid (D) TOPOIOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: Met He Tyr Thr Met Lys Lys Val His Ala Lsu Trp Ala Ser Val Cys -28 -25 -20 -15 Lsu Lsu Leu Asn Leu Ala E>ro Ala I>ro Leu Asn Ala Asp Ser Glu Glu -10 -5 1 Asp Glu Glu His Thr He He Thr Asp Thr Glu Leu Pro Pro Leu Lys 5 10 15 20 Leu Met His Ser Fhe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Lys 25 30 35 Ala He Met Lys Arg Fhe Fhe Fhe Asn He Fhe Thr Arg Gin Cys Glu 40 45 50 Glu Fhe He Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser 55 60 65 Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp Asn Ala Asn Arg He 70 75 80 He Lys Thr Thr Leu Gin Gin Glu Lys Pro Asp Ehe Cys Ehe Leu Glu 85 90 95 100 Glu Asp I>ro Gly He Cys Arg Gly Tyr He Thr Arg Tyr Phe Tyr Asn 105 110 115 Asn Gin Thr Lys Gin Cys Glu Arg Fhe Lys Tyr Gly Gly Cys Leu Gly 120 125 130 Asn Met Asn Asn Phe Glu Thr Leu Glu Glu Cys Lys Asn He Cys Glu 135 140 145 Asp Gly Pro Asn Gly Phe Gin Val Asp Asn Tyr Gly Thr Gin Leu Asn 150 155 160 Ala Val Asn Asn Ser Leu Thr Pro Gin Ser Thr Lys Val I>ro Ser Leu 165 170 175 180 Fhe Glu Fhe His Gly Pro Ser Trp Cys Leu Thr Pro Ala Asp Arg Gly 185 190 195 Leu Cys Arg Ala Asn Glu Asn Arg Fhe Tyr Tyr Asn Ser Val He Gly 200 205 210 Lys Cys Arg Pro Fhe Lys Tyr Ser Gly Cys Gly Gly Asn Glu Asn Asn 215 220 225 Phe Thr Ser Lys Gin Glu Cys Leu Arg Ala Cys Lys Lys Gly Phe He 230 235 240 Gin Arg He Ser Lys Gly Gly Lsu He Lys Thr Lys Arg Lys Arg Lys 245 250 255 260 Lys Gin Arg Val Lys He Ala Tyr Glu Glu He Ehe Val Lys Asn Met 265 270 275 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: ENA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 76..234 (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION: 76..222 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 223..234 (xi) SEQUENCE DESCRIFTTON: SEQ ID NO: 10: GAATTCATTC AAGAATACTT CAAACAAGAA GATTACAAAC TATCAATTTC ATACACAATA 60 TAAAOGAITA AAAGA ATG AAG GCT GTT TTC TTG GTT TTG TCC TTG ATC GGA 111 Met Lys Ala Val Phe Leu Val Leu Ser Lsu He Gly -49 -45 -40 TTC TGC TGG GCC CAA CCA CTC ACT GGC GAT GAA TCA TCT CTT GAG ATT 159 Phe Cys Trp Ala Gin Pro Val Thr Gly Asp Glu Ser Ser Val Glu He -35 -30 -25 CCG GAA GAG TCT CTG ATC ATC GCT GAA AAC ACC ACT TTG GCT AAC CTC 207 I>ro Glu Glu Ser Leu He He Ala Glu Asn Thr Thr Lsu Ala Asn Val -20 -15 -10 GCC ATG GCT AAG AGA GAT TCT GAG GAA 234 Ala Met Ala Lys Arg Asp Ser Glu Glu -5 l (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 53 amino acids (B) TYPE: amino acid (D) TOPOIOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: Met Lys Ala Val Phe Leu Val Leu Ser Leu He Gly Fhe Cys Trp Ala -49 -45 -40 -35 Gin Pro Val Thr Gly Asp Glu Ser Ser Val Glu He Pro Glu Glu Ser -30 -25 -20 Lsu He He Ala Glu Asn Thr Thr Leu Ala Asn Val Ala Met Ala Lys -15 -10 -5 Arg Asp Ser Glu Glu 1 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 190 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: DNA (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 17..190 (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION: 17..178 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 179..190 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GAATTCAAAC TAAAAA ATG AAG CTT AAA ACT CTA AGA TCT GCG GTC CTT 49 Met Lys Lsu Lys Thr Val Arg Ser Ala Val Lsu -54 -50 -45 TCG TCA CTC TTT GCA TCG CAG GTC CTA GCT CAA CCA GTC ACT GGC GAT 97 Ser Ser Leu Fhe Ala Ser Gin Val Lsu Gly Gin Pro Val Thr Gly Asp -40 -35 -30 GAA TCA TCT GTT GAG ATT CCG GAA GAG TCT CTG ATC ATC GCT GAA AAC 145 Glu Ser Ser Val Glu He I>ro Glu Glu Ser Lsu He He Ala Glu Asn -25 -20 -15 ACC ACT TTG GCT AAC GTC GCC ATG GCT AAG AGA GAT TCT GAG GAA 190 Thr Thr Leu Ala Asn Val Ala Met Ala Lys Arg Asp Ser Glu Glu -10 -5 1 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE OiARACTERISTTCS: (A) LENGTH: 58 amino acids (B) TYPE: amino acid (D) TOPOIOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: Met Lys Leu Lys Thr Val Arg Ser Ala Val Leu Ser Ser Leu Fhe Ala -54 -50 -45 -40 Ser Gin Val Lsu Gly Gin Pro Val Thr Gly Asp Glu Ser Ser Val Glu -35 -30 -25 He Pro Glu Glu Ser Leu He He Ala Glu Asn Thr Thr Leu Ala Asn -20 -15 -10 Val Ala Met Ala Lys Arg Asp Ser Glu Glu -5 1 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEENESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: ENA (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: AITIGCTGCC ATGCTACTTT CAGAAGG 27 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: DNA (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: CAACCAATAG ACACGOCTAA AG GGCCTA CAGCATGATT ACGATACAGA GATCTTGGAG 60 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 62 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: ENA (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: (XAAGATCTC TGTATCCTAA T^TGCTCTA GGCXIETCITT ACGOΞTGTCT ATTGGTTGGG 60 CC 62 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 87 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: DNA (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: GTACCAAAAT AATGAAACTG AAAACTGTAA GATCTGCGGT CETITCGTCA CTCTTTGCAT 60 CTCAGCTCCT TGGCCAACCA ATAGACA 87 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 87 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: ENA (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: CGCGTGTCTA TTGGTTGGCC AAGGACCTGA GATGCAAAGA GTGACGAAAG GACCGCAGAT 60 CTTACAGTTT TCAGTTTCTA TAITTTG 87 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: DNA (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIFTION: SEQ ID NO: 19: TAACGTCGC 9 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEENESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: ENA (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: CATGGOGACG 10 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEENESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: ENA (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIFTION: SEQ ID NO: 21: CTTGGCCAAC CATCGAAATT GAAACCAG 28 (2) INFORMATION FOR SEQ ID NO: 22 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: DNA (Vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIFTTON: SEQ ID NO: 22: CTAGCTGGTT TCAATTTCGA TGGTTGGC 28 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 88 base pairs (B) TYPE: nucleic acid (C) STRANDEENESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: ENA (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIFTION: SEQ ID NO: 23: AAITCAAACT AAAAAATGAA GCTTAAAACT GTAAGATCTG CGGTCX3TTC GTCACTCTTT 60 GCATOGCAGG TCCTAGGTCA ACCAGTCA 88 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 81 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOIOGY: linear (ii) MOLECULE TYPE: DNA (vi) ORIGINAL SOURCE: (A) ORGANISM: synthetic (xi) SEQUENCE DESCRIFTION: SEQ ID NO: 24: CTGGTTGACC TAGGACCTGC GATGCAAAGA GTGACGAAAG GACCGCAGAT CTTACAGTIT 60 TAAGCΓΓCAT TTΠTAGTTT G 8i

Claims: CLAIMS 1. A DNA construct comprising the following sequence 5•-P-SP-(LP) n -PS-HP-3 ' wherein 5 P is a promoter sequence, SP is a DNA sequence encoding the yeast aspartic protease 3 (YAP3) signal peptide, LP is a DNA sequence encoding a leader peptide, n is 0 or 1, 10 PS is a DNA sequence encoding a peptide defining a yeast processing site, and HP is a DNA sequence encoding a polypeptide which is heterologous to a selected host organism. 2. A DNA construct according to claim 1, wherein the promoter 15 sequence is selected from the Saccharomyces cerevisiae MFαl, TPI, ADH, BAR1 or PGK promoter, or the Schizosaccharomvces pombe ADH promoter. 3. A DNA construct according to claim 1, wherein the YAP3 signal peptide is encoded by the following DNA sequence 20 ATG AAA CTG AAA ACT GTA AGA TCT GCG GTC CTT TCG TCA CTC TTT GCA TCT CAG GTC CTT GGC (SEQ ID No:l) or a suitable modification thereof encoding a peptide with a high degree of homology to the YAP3 signal peptide. 4. A DNA construct according to claim 1, wherein n is 1. 255. A DNA construct according to claim 5, wherein the leader peptide is a yeast MFαl leader peptide or a synthetic leader peptide. 6. A DNA construct according to claim 1, wherein PS is a DNA sequence encoding Lys-Arg, Arg-Lys, Lys-Lys, Arg-Arg or Ile- Glu-Gly-Arg. 7. A DNA construct according to claim 1, wherein the 5 heterologous polypeptide is selected from the group consisting of aprotinin, tissue factor pathway inhibitor or other protease inhibitors, insulin or insulin precursors, human or bovine growth hormone, interleukin, glucagon, glucagon-like peptide 1, tissue plasminogen activator, transforming growth factor α or 10 β , platelet-derived growth factor, enzymes, or a functional analogue thereof. 8. A DNA construct according to claim 1, which further comprises a transcription termination sequence. 9. A DNA construct according to claim 8, wherein the 15 transcription termination sequence is the TPI terminator. 10. A recombinant expression vector comprising a DNA construct according to any of claims 1-9. 11. A cell transformed with a vector according to claim 10. 12. A cell according to claim 11, which is a fungal cell. 2013. A cell according to claim 12, which is a yeast cell. 14. A cell according to claim 13, which is a cell of Saccharomyces. Schizosaccharomvces. Kluyvero yces. Hansenula or Yarrowia. 15. A cell according to claim 14, which is a cell of 25 Saccharomyces cerevisiae or Schizosaccharomvces pombe. 16. A method of producing a heterologous polypeptide, the method comprising culturing a cell which is capable of expressing a heterologous polypeptide and which is transformed with a DNA construct according to any of claims 1-9 in a suitable medium to obtain expression and secretion of the heterologous polypeptide, after which the heterologous polypeptide is recovered from the medium.

Inventors: CHRISTIANSEN LARS, PETERSEN JENS G LITSKE, CHRISTIANSEN, LARS, PETERSEN, JENS, G., LITSKE
Applicants: CHRISTIANSEN LARS, NOVONORDISK AS, PETERSEN JENS G LITSKE, CHRISTIANSEN, LARS, NOVO NORDISK A/S, PETERSEN, JENS, G., LITSKE
Application year: 1994
Main classification: C12N15
IPC codes: C07K14, C12N1, C12N9, C12N15, C12P21, C12R1